Research programme: small molecule therapeutics - Infinity/Johnson & Johnson

Drug Profile

Research programme: small molecule therapeutics - Infinity/Johnson & Johnson

Latest Information Update: 16 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Infinity Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 Dec 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 14 Mar 2007 Infinity Pharmaceuticals has recognised $US1 million revenue from delivery of compounds to Johnson & Johnson under this agreement
  • 31 Dec 2005 Infinity has amended the agreement to allow for a reduction in the number of compounds to be delivered to Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top